HER2 mutation
1 drugsPredictive biomarker for patient selection in 5 indications
1
Approved Drugs
5
Indications
1
Companies
HER2 mutation is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Unresectable or metastatic HER2-positive breast cancer, Unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer, Unresectable or metastatic HER2-low breast cancer. Explore the targeted therapies, indications, testing methods, and companies developing HER2 mutation drugs below.
Search HER2 mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting HER2 mutation
| Drug | Company | Therapeutic Area |
|---|---|---|
| ENHERTU | DAIICHI SANKYO INC | Oncology |
HER2 mutation Indications
Unresectable or metastatic HER2-positive breast cancer Unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer Unresectable or metastatic HER2-low breast cancer Unresectable or metastatic HER2-mutant non-small cell lung cancer Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma